OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
95016058

950160.KQ

Biotechnology & Medical ResearchVerified

The company's capital structure is characterized by a debt-to-equity ratio of 1.24, indicating a moderate reliance on debt financing. Its liquidity position is weak, with a current ratio of 0.24, suggesting limited short-term liquidity to cover immediate obligations. The company holds $47.2 million in cash and equivalents, but this is offset by $55.4 million in long-term debt, resulting in a net cash position of -$8.2 million. Profitability metrics are severely negative, with a return on equity of -303.22% and a return on assets of -45.83%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating loss of $15.7 million and net loss of $135.4 million further underscore the company's financial distress. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The absence of positive revenue trends, combined with significant operating and net losses, suggests a challenging outlook for near-term growth. The company's capital expenditures of $82.6 million indicate ongoing investment, but this has not translated into improved financial performance. The company faces significant liquidity and dilution risks. The liquidity risk is rated as medium, with a weak current ratio and negative net cash position. The dilution risk is rated as low, but the company's financial position may necessitate future equity issuances to fund operations or reduce debt. No recent dilutive events have been disclosed. Recent events include a strong buy recommendation from one analyst, with a mean price target of $170,000. However, the company's financial performance does not currently support this optimistic outlook. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or financial health.

30-day price · 950160+9800.00 (+9.9%)
Low$89600.00High$149000.00Close$109100.00As of26 May, 00:00 UTC
Profile
Company950160.KQ
Ticker950160.KQ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. The company operates in the healthcare diagnostics segment, developing and commercializing diagnostic solutions for disease detection and monitoring.

Classification. The company is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

The company's capital structure is characterized by a debt-to-equity ratio of 1.24, indicating a moderate reliance on debt financing. Its liquidity position is weak, with a current ratio of 0.24, suggesting limited short-term liquidity to cover immediate obligations. The company holds $47.2 million in cash and equivalents, but this is offset by $55.4 million in long-term debt, resulting in a net cash position of -$8.2 million. Profitability metrics are severely negative, with a return on equity of -303.22% and a return on assets of -45.83%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating loss of $15.7 million and net loss of $135.4 million further underscore the company's financial distress. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another. The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The absence of positive revenue trends, combined with significant operating and net losses, suggests a challenging outlook for near-term growth. The company's capital expenditures of $82.6 million indicate ongoing investment, but this has not translated into improved financial performance. The company faces significant liquidity and dilution risks. The liquidity risk is rated as medium, with a weak current ratio and negative net cash position. The dilution risk is rated as low, but the company's financial position may necessitate future equity issuances to fund operations or reduce debt. No recent dilutive events have been disclosed. Recent events include a strong buy recommendation from one analyst, with a mean price target of $170,000. However, the company's financial performance does not currently support this optimistic outlook. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or financial health.
Key takeaways
  • The company is experiencing significant financial distress, with large operating and net losses.
  • Liquidity is weak, with a current ratio of 0.24 and a negative net cash position.
  • Profitability metrics are severely negative, indicating poor returns for shareholders and inefficient asset utilization.
  • The company's revenue is concentrated in a single segment, increasing exposure to market-specific risks.
  • Analysts have issued a strong buy recommendation, but the company's financial performance does not currently support this outlook.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$3.6M
Gross profit$481.8k
Operating income-$15.7M
Net income-$135.4M
R&D
SG&A
D&A
SBC
Operating cash flow-$16.9M
CapEx-$82.6M
Free cash flow-$217.4M
Total assets$295.5M
Total liabilities$250.8M
Total equity$44.7M
Cash & equivalents$47.2M
Long-term debt$55.4M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$44.7M
Net cash-$8.2M
Current ratio0.2
Debt/Equity1.2
ROA-45.8%
ROE-3.0%
Cash conversion12.0%
CapEx/Revenue-22.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
Metric950160Activity
Op margin-432.7%-227.5% medp25 -1250.6% · p75 -3.5%below median
Net margin-3733.3%-194.5% medp25 -1233.8% · p75 0.8%bottom quartile
Gross margin13.3%53.0% medp25 25.9% · p75 75.7%bottom quartile
CapEx / revenue-2277.0%-8.2% medp25 -35.2% · p75 -2.5%bottom quartile
Debt / equity124.0%1.2% medp25 0.0% · p75 17.4%top quartile
Observations
IR observations
Mean price target170,000.00 USD
Median price target170,000.00 USD
High price target170,000.00 USD
Low price target170,000.00 USD
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-86.00 USD
Mean revenue estimate6,000,000,000 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 19:38 UTC#80afe3a7
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 05:03 UTCJob: f6a18736